(Q44631764)

English

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

scientific article published on November 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes (English)

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

type-1 diabetes

0 references

1 reference

based on heuristic

inferred from title

regular insulin

1 reference

based on heuristic

inferred from title

internal medicine

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

author name string

Christian Weyer

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Alan Gottlieb

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Karen Lutz

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sherwyn Schwartz

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Maria Gutierrez

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Yan Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dennis D. Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578242

25 March 2024

James A. Ruggles

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578242

25 March 2024

Orville G. Kolterman

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578242

25 March 2024

David G. Maggs

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578242

25 March 2024

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3074-3079

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Aerosol infectivity of Legionella pneumophila

1

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Insulin analogues and their potential in the management of diabetes mellitus

2

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Standards of medical care for patients with diabetes mellitus

3

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

5

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

6

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Amylin concentrations and glucose control

8

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Glucagon physiology and pathophysiology

9

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy

10

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM

11

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.

12

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus

13

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

14

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

15

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

16

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

17

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial

18

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

19

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

20

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

23

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin

25

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment

26

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects

27

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

29

1 reference

10.2337/DIACARE.26.11.3074

https://api.crossref.org/works/10.2337/DIACARE.26.11.3074

25 March 2024

Identifiers

10.2337/DIACARE.26.11.3074

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44631764&oldid=2112655885"